SEC Comment Letter for Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Sep 10, 2019
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: Sept. 10, 2019 · CIK: 0001540159 · Accession: 0000000000-19-013355
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233567
Letter
September 9, 2019 Pardeep Nijhawan Chief Executive Officer Edesa Biotech, Inc. 100 Spy Court Markham, ON L3R 5H6 Canada Re:Edesa Biotech, Inc. Registration Statement on Form S-3 Filed August 30, 2019 File No. 333-233567 Dear Dr. Nijhawan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jonathan Friedman
Show Raw Text
September 9, 2019
Pardeep Nijhawan
Chief Executive Officer
Edesa Biotech, Inc.
100 Spy Court
Markham, ON L3R 5H6 Canada
Re:Edesa Biotech, Inc.
Registration Statement on Form S-3
Filed August 30, 2019
File No. 333-233567
Dear Dr. Nijhawan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jonathan Friedman